Literature DB >> 25931178

Non-immunoglobulin scaffolds: a focus on their targets.

Katja Škrlec1, Borut Štrukelj2, Aleš Berlec3.   

Abstract

Non-immunoglobulin (non-Ig) scaffolds are, in contrast to antibodies, small single-domain proteins that require no post-translational modification, often lack disulfide bonds, and can undergo straightforward multimerization. Among the 20 different types of non-Ig scaffolds, Adhirons, Alphabodies, Centyrins, Pronectins, Repebodies, Affimers, and Obodies have been introduced in the past 4 years. 102 proteins have been specifically targeted by 139 different non-Ig scaffold binders. The most frequent application of non-Ig scaffolds is in the treatment and diagnosis of cancer and inflammatory diseases, and 10 non-Ig scaffolds have already been tested in clinical trials. Recently, non-Ig scaffolds have often been used in research as structure determination chaperones, for intracellular monitoring of post-translational modifications, and as antibody alternatives for microscopy, flow cytometry, and Western blotting.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antibody alternatives; binders; non-immunoglobulin scaffolds

Mesh:

Substances:

Year:  2015        PMID: 25931178     DOI: 10.1016/j.tibtech.2015.03.012

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  59 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

Review 2.  Nanobodies as Probes for Protein Dynamics in Vitro and in Cells.

Authors:  Oleg Y Dmitriev; Svetlana Lutsenko; Serge Muyldermans
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

3.  Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders.

Authors:  Max A Kruziki; Vidur Sarma; Benjamin J Hackel
Journal:  ACS Comb Sci       Date:  2018-06-05       Impact factor: 3.784

4.  A versatile nanobody-based toolkit to analyze retrograde transport from the cell surface.

Authors:  Dominik P Buser; Kai D Schleicher; Cristina Prescianotto-Baschong; Martin Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-18       Impact factor: 11.205

5.  Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Authors:  Junpeng Qi; Xiuling Li; Haiyong Peng; Erika M Cook; Eman L Dadashian; Adrian Wiestner; HaJeung Park; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

Review 6.  Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.

Authors:  Cuong Thach Nguyen; Yehudi Bloch; Katarzyna Składanowska; Savvas N Savvides; Iannis E Adamopoulos
Journal:  Clin Immunol       Date:  2018-09-06       Impact factor: 3.969

Review 7.  The variable lymphocyte receptor as an antibody alternative.

Authors:  Elizabeth A Waters; Eric V Shusta
Journal:  Curr Opin Biotechnol       Date:  2018-03-26       Impact factor: 9.740

Review 8.  Engineered protein scaffolds as leads for synthetic inhibitors of protein-protein interactions.

Authors:  Michael G Wuo; Paramjit S Arora
Journal:  Curr Opin Chem Biol       Date:  2018-05-24       Impact factor: 8.822

9.  Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.

Authors:  Jie Ying Chan; Benjamin J Hackel; Douglas Yee
Journal:  Mol Cancer Ther       Date:  2017-05-03       Impact factor: 6.261

10.  Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.

Authors:  Susana Frago; Ryan D Nicholls; Madeleine Strickland; Jennifer Hughes; Christopher Williams; Lee Garner; Mirvat Surakhy; Rory Maclean; Dellel Rezgui; Stuart N Prince; Oliver J Zaccheo; Daniel Ebner; Sabina Sanegre; Sheng Yu; Francesca M Buffa; Matthew P Crump; Andrew Bassim Hassan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.